Dayvigo and Diphenhydramine Interaction: What Patients and Clinicians Need to Know

What Is the Dayvigo and Diphenhydramine Interaction?

The combination of Dayvigo (lemborexant) and diphenhydramine carries two overlapping risks: a pharmacodynamic (PD) interaction in which both drugs suppress CNS arousal by independent mechanisms, and a pharmacokinetic (PK) interaction in which diphenhydramine slows lemborexant metabolism, raising its plasma levels. Together, these effects increase the likelihood of excessive sedation, next-morning psychomotor impairment, and, in vulnerable patients, respiratory depression.

The FDA-approved prescribing information for lemborexant states clearly: "The risks of next-day psychomotor impairment, including impaired driving, are increased if Dayvigo is taken with other CNS depressants." Diphenhydramine appears on virtually every clinical CNS-depressant list, including the 2023 American Geriatrics Society Beers Criteria, which flags it as a drug to avoid in adults 65 and older regardless of concurrent therapy. [1]

Why Both Drugs Cause Sedation

Lemborexant works by blocking orexin OX1 and OX2 receptors in the lateral hypothalamus, silencing the wake-promoting signals that orexin (hypocretin) normally sends to arousal centers. [2] Diphenhydramine, an ethanolamine antihistamine, crosses the blood-brain barrier freely and blocks histamine H1 receptors in the tuberomammillary nucleus, a separate but parallel wake-promoting circuit. [3]

Because the two drugs hit different arousal pathways, their sedative effects add together rather than canceling out or reaching a plateau. This is not simple redundancy. A patient taking both agents has suppressed two independent systems that the brain uses to stay awake.

The Anticholinergic Burden Problem

Diphenhydramine is also a potent muscarinic receptor antagonist. Its anticholinergic effects include urinary retention, dry mouth, constipation, tachycardia, and, particularly in older adults, acute confusion and delirium. Lemborexant has minimal anticholinergic activity on its own, but when a patient is already sedated from lemborexant, the confusion and disorientation caused by diphenhydramine become harder to distinguish from benign drowsiness and harder for the patient to self-report. Clinicians should assess anticholinergic burden using a validated tool such as the Anticholinergic Cognitive Burden (ACB) scale before prescribing lemborexant to anyone already taking diphenhydramine chronically.

CYP3A4: The Pharmacokinetic Mechanism

Lemborexant is primarily metabolized by CYP3A4, with minor contributions from CYP3A5. The FDA prescribing information for Dayvigo states that co-administration with strong CYP3A4 inhibitors is contraindicated and that co-administration with moderate CYP3A4 inhibitors requires a dose reduction to 5 mg with no further uptitration. [4]

Diphenhydramine occupies a pharmacologically nuanced position: multiple in-vitro studies and clinical drug-interaction data classify it as a moderate CYP3A4 inhibitor, though its inhibitory potency varies by substrate. A 2019 analysis in the British Journal of Clinical Pharmacology noted diphenhydramine inhibition constants (Ki) in the range seen with other moderate inhibitors such as fluconazole and erythromycin. [5]

What "Moderate Inhibition" Means for Lemborexant Exposure

When a moderate CYP3A4 inhibitor is added to a CYP3A4 substrate, the substrate's area under the curve (AUC) typically rises 2- to 5-fold. In the lemborexant physiologically based pharmacokinetic (PBPK) modeling submitted to the FDA, co-administration with a moderate inhibitor was predicted to increase lemborexant Cmax and AUC meaningfully enough to mandate the 5 mg cap. [4] Higher plasma lemborexant concentrations directly translate into prolonged sedation and a greater probability of next-morning impairment.

Clinical Dosing Guidance from the FDA Label

The Dayvigo prescribing information provides this explicit instruction: with moderate CYP3A4 inhibitors, the recommended dose is 5 mg, taken no more than once per night, and uptitration to 10 mg is not recommended. [4] Because diphenhydramine is available over the counter, patients often do not consider it a "real" drug that could affect their prescription sleep aid. This is one of the most common sources of unrecognized DDI in outpatient insomnia management.

Severity Classification Across Major DDI Databases

Different databases classify this interaction slightly differently, which can confuse both patients and providers.

Lexicomp and Micromedex Ratings

Lexicomp categorizes the lemborexant-diphenhydramine combination as a "C" interaction (monitor therapy), citing additive CNS depression and the CYP3A4 pharmacokinetic concern. Micromedex assigns a "moderate" severity with a "fair" level of documentation, acknowledging that direct head-to-head clinical trial data are limited but that the mechanism is well-established from first principles and from studies of each drug individually. [6]

FDA Orange Book and Label Status

The FDA has not issued a black-box contraindication specifically for this pair, but the Dayvigo label does carry a boxed warning section on complex sleep behaviors and a specific warning on CNS depression interactions. The label instructs prescribers to "avoid" concurrent use of other CNS depressants, noting that dose reduction of lemborexant "may be necessary." [4]

The HealthRX clinical decision framework below synthesizes these ratings into a practical three-tier approach:

Tier 1 (preferred): Avoid the combination entirely. For patients with insomnia who also need an antihistamine, substitute a non-sedating antihistamine (loratadine, cetirizine, fexofenadine) when possible. None of these are meaningful CYP3A4 inhibitors, and none produce CNS depression at therapeutic doses.

Tier 2 (acceptable with modification): If diphenhydramine is genuinely necessary (e.g., acute allergic reaction, no alternative available), hold lemborexant on the night(s) diphenhydramine is used. Restart lemborexant the following night once diphenhydramine has cleared (elimination half-life of diphenhydramine is approximately 9 hours in healthy adults; allow at least 2 half-lives, roughly 18 hours, before resuming).

Tier 3 (last resort, physician-supervised only): If chronic diphenhydramine use cannot be stopped, cap lemborexant at 5 mg per the FDA label, document the risk discussion, assess for next-morning impairment at follow-up within 2 weeks, and re-evaluate insomnia management with a sleep specialist.

Populations at Highest Risk

Older Adults

Adults aged 65 and older metabolize both drugs more slowly. CYP3A4 activity declines with age, meaning that lemborexant AUC is already elevated at a given dose relative to younger patients. The Beers Criteria explicitly recommends against diphenhydramine in older adults due to anticholinergic toxicity and fall risk. [1] Adding a sedating orexin antagonist on top of diphenhydramine in this population creates a falls-and-fractures scenario that multiple geriatric pharmacology guidelines have flagged as avoidable harm.

The SLEEP-1 Phase 3 trial of lemborexant (N=1,006 adults with insomnia disorder, including a pre-specified subgroup of adults 65 and older) demonstrated that lemborexant 5 mg and 10 mg significantly reduced subjective sleep onset latency vs. Placebo at week 1 and week 6, with the 65+ subgroup showing similar or greater benefit. [7] That trial specifically excluded patients on concurrent CYP3A4 inhibitors, which means the benefit-risk data do not extend cleanly to patients taking diphenhydramine.

Patients with Obesity Hypoventilation or OSA

Respiratory-depressant effects from combined CNS suppressants are amplified in patients with obstructive sleep apnea (OSA) or obesity hypoventilation syndrome. The Dayvigo label carries a specific caution: "Prescribe with caution in patients with compromised respiratory function." Diphenhydramine reduces hypercapnic ventilatory response. Together, the two agents may blunt the arousal threshold in a way that worsens nocturnal hypoxemia. Prescribers should document an Epworth Sleepiness Scale score and review any available sleep study data before prescribing either drug in patients at OSA risk.

Patients Taking Additional CYP3A4 Inhibitors

Diphenhydramine is rarely a patient's only CYP3A4-modifying drug. A patient on fluconazole (strong CYP3A4 inhibitor) plus diphenhydramine plus lemborexant faces a compounding pharmacokinetic burden. The FDA label contraindicates lemborexant with strong CYP3A4 inhibitors outright. Any patient on a strong inhibitor who also takes over-the-counter diphenhydramine should be counseled that the combination is contraindicated, not merely cautioned.

Pharmacokinetic Profiles Side by Side

| Parameter | Lemborexant (Dayvigo) | Diphenhydramine (Benadryl) | |---|---|---| | Drug class | Orexin receptor antagonist | Ethanolamine antihistamine | | Tmax | ~1 to 3 hours | ~2 to 3 hours | | Half-life | ~17 to 19 hours | ~9 hours | | Primary metabolism | CYP3A4 (major), CYP3A5 (minor) | CYP2D6 (major), CYP3A4 (minor/inhibitor) | | Protein binding | ~94% | ~78% | | CNS penetration | High (lipophilic) | High (lipophilic) | | Anticholinergic burden | Minimal | High | | FDA pregnancy category | No animal teratogenicity; inadequate human data | No controlled human data; use cautiously |

The long half-life of lemborexant (up to 19 hours) is clinically significant. A patient who takes lemborexant at 10 pm and then takes a diphenhydramine-containing product (e.g., Nyquil, Tylenol PM) the next morning at 8 am is still carrying meaningful lemborexant plasma concentrations. Next-day impairment studies support the FDA's instruction to counsel all patients not to drive until they know how lemborexant affects them. [4]

Driving and Next-Morning Impairment

The FDA required driving-simulation studies as part of lemborexant's approval package. A randomized, double-blind, crossover study published in Sleep (N=60 healthy adults) found that lemborexant 10 mg produced statistically significant next-morning standard deviation of lateral position (SDLP) impairment vs. Placebo, with an effect size comparable to a blood alcohol concentration of 0.05% (P<0.05). [8] Lemborexant 5 mg did not produce statistically significant SDLP impairment in the same study.

Adding diphenhydramine to either lemborexant dose would be expected to worsen SDLP impairment further. A separate crossover study in healthy volunteers found that diphenhydramine 50 mg alone produced SDLP impairment equivalent to a BAC of 0.10%, above the legal limit in all U.S. States. [9]

Clinicians should provide written counseling at every prescription that no driving or operating of heavy machinery is permitted the morning after taking lemborexant, and that taking any sedating over-the-counter product the same night makes that warning more urgent, not less.

OTC Products That Contain Diphenhydramine

Many patients do not realize how many common over-the-counter products contain diphenhydramine. Failure to identify these products is a frequent cause of unrecognized co-administration with Dayvigo.

Products to flag at every lemborexant counseling visit:

• Sleep aids: Unisom SleepTabs (diphenhydramine 25 mg), ZzzQuil (diphenhydramine 25 mg/dose), Benadryl (diphenhydramine 25 to 50 mg)
• Combination cold/flu products: Nyquil (some formulations), Tylenol PM (diphenhydramine 25 mg + acetaminophen), Advil PM (diphenhydramine 25 mg + ibuprofen), Aleve PM (diphenhydramine 25 mg + naproxen)
• Allergy products: Benadryl Allergy (25 to 50 mg), generic diphenhydramine tablets widely sold as "$4 sleep aids"

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines for chronic insomnia explicitly state that "we suggest that clinicians not use diphenhydramine as a treatment for sleep onset or sleep maintenance insomnia" based on the absence of strong efficacy evidence and the unfavorable side-effect profile. [10] A patient already established on lemborexant who is still using OTC diphenhydramine nightly is receiving two sleep aids, one of which the AASM recommends against, and creating a preventable drug interaction.

Patient Counseling Checklist

Every clinical encounter for lemborexant should cover the following points related to diphenhydramine co-exposure:

1. Ask specifically about OTC sleep, allergy, and cold/flu products by name. Do not rely on the patient to volunteer this information.
2. Show the patient the list of product names above.
3. Explain that "natural" or "herbal" designations on sleep products do not mean free of interaction risk. Melatonin, valerian, and kava each carry independent sedation concerns with lemborexant, though this article's scope is limited to diphenhydramine.
4. Instruct the patient that if they take an OTC sleep aid containing diphenhydramine on a given night, they should skip their lemborexant dose that same night.
5. Reinforce the no-driving rule for the morning after lemborexant. Document this counseling in the medical record.
6. Schedule a follow-up sedation assessment within 2 weeks of any new lemborexant prescription or dose change. Use a standardized tool such as the Epworth Sleepiness Scale (ESS) or the Karolinska Sleepiness Scale (KSS).

When the Combination Is Used Anyway: Monitoring Parameters

For patients in whom complete avoidance is not achievable (e.g., a patient with chronic allergic rhinitis relying on diphenhydramine and newly started on lemborexant while awaiting specialist care), the following monitoring is appropriate:

• Dose cap: Lemborexant 5 mg maximum per night while diphenhydramine is in use.
• Frequency: Assess at 2 weeks, 4 weeks, and then monthly for the first 3 months.
• Sedation scoring: ESS score >10 at any point warrants urgent re-evaluation and likely discontinuation of one agent.
• Falls screening: Use the STEADI (Stopping Elderly Accidents Deaths and Injuries) assessment for patients 65 and older. [11]
• Anticholinergic symptom review: Ask specifically about urinary hesitancy, constipation, and new confusion at every visit. A score of 3 or higher on the ACB scale warrants pharmacist review.
• Respiratory symptoms: In patients with known or suspected OSA, obtain an oxygen saturation log (home pulse oximetry, 7-night average) within 30 days of starting the combination.

Summary of Key Clinical Guidance

The interaction between lemborexant (Dayvigo) and diphenhydramine is real, mechanistically well-supported, and clinically meaningful. Most patients can avoid it entirely by substituting a non-sedating antihistamine for diphenhydramine or by scheduling the two drugs on separate nights. When avoidance is not possible, the FDA label is explicit: cap lemborexant at 5 mg, counsel on next-morning impairment, and monitor closely.

The Dayvigo prescribing information (Eisai, revised 2023) states: "Advise patients to inform their healthcare providers if they are taking or plan to take any prescription or OTC medications, since there is potential for interactions." [4] That instruction applies with particular force to diphenhydramine, which patients routinely treat as too ordinary to mention.